Nick Leschly and Giovanni Caforio (Via Jeff Rumans and AP Images)

FDA slams blue­bird and Bris­tol My­ers with a sur­prise RTF on ide-cel, but ex­ecs in­sist they can over­come set­back quick­ly

Bris­tol My­ers and their part­ners at blue­bird have been slammed with a refuse-to-file let­ter from the FDA for their close­ly watched myelo­ma drug ide-cel …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.